Substantial basic science and clinical evidence suggests that excess tumor necrosis factor-alpha (TNF-alpha) is centrally involved in the pathogenesis of Alzheimer's disease. In addition to its ...

In patients with non-radiographic axial spondyloarthritis who achieved inactive disease with etanercept, approximately 25% remained flare-free at 40 weeks after ceasing treatment, according to data ...

Etanercept, which blocks the action of tumor necrosis factor, reduces disease activity in patients with long-standing rheumatoid arthritis. Its efficacy in reducing disease activity and preventing ...

Please provide your email address to receive an email when new articles are posted on . Originator- and biosimilar-receiving patients with rheumatoid arthritis demonstrated similar disease activity at ...

A 20-year-old female presented with a history of psoriasis and psoriatic arthritis since childhood. She started treatment with etanercept (Enbrel ®) 1 month previously. One day after a subcutaneous ...

Lupin is introducing Rymti, its first biosimilar in Canada, through its partner Sandoz Canada (Sandoz). Rymti is indicated for the treatment of moderate to severe active rheumatoid arthritis, juvenile ...